Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

192.45 -2.55 (-1.31%)
Official Closing Price Updated: 7:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,991,010
Open 193.89
Bid (Size) 191.20 (1)
Ask (Size) 192.75 (1)
Prev. Close 195.00
Today's Range 191.16 - 194.00
52wk Range 163.81 - 218.66
Shares Outstanding N/A
Dividend Yield 3.41%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
Boeing, Joby Aviation, Oracle And A Health Care Stock: CNBC's 'Final Trades'
The investment landscape is shifting as companies show resilience and innovation, prompting investors to reassess portfolios. AbbVie, Boeing, Oracle, and Joby Aviation mentioned as potential... 
Via Benzinga

Performance

YTD
+7.3%
+7.3%
1 Month
+0.5%
+0.5%
3 Month
+9.9%
+9.9%
6 Month
+9.9%
+9.9%
1 Year
+13.3%
+13.3%

More News

Read More
What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill
Via The Motley Fool
Topics Intellectual Property
AbbVie Enters Licensing Agreement For IGI Therapeutics’ Experimental Oncology Drug: Retail Cheers
Via Stocktwits
Topics Product Recall
Why Is AbbVie Stock Trading Higher On Thursday?
Via Benzinga
Trump Threatens 200% Tariffs On Drug Imports, Says Big Pharma Will Get Some Time 'To Get Their Act Together'
Via Stocktwits
Topics ETFs Economy Government
3 No-Brainer Stocks to Buy in July
Via The Motley Fool
2 Dividend Stocks to Buy for Decades of Passive Income
Via The Motley Fool
Topics Intellectual Property
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Via The Motley Fool
Topics Economy Intellectual Property
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
Via Benzinga
Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial
Via Benzinga
3 Profitable Stocks Skating on Thin Ice
Via StockStory
HDV Is a Popular Dividend ETF for Passive Income. But Is It the Best?
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
AbbVie To Acquire Capstan Therapeutics For Up To $2.1 Billion To Boost Immunology Portfolio As Humira Sales Drop: Stock Gains In Morning Trade
Via Stocktwits
Topics Intellectual Property
3 Dividend Stocks to Double Up on Right Now
Via The Motley Fool
Topics Government World Trade
Got $500? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Topics Artificial Intelligence
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
Via Investor's Business Daily
Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere
Via Benzinga
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
Via Benzinga
AbbVie's Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial
Via Benzinga
AbbVie’s Migraine Drug Yields Positive Outcome In Late-Stage Study Versus Topiramate, But Fails To Draw Retail Cheer
Via Stocktwits
Topics Economy
AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine
Via Benzinga
Topics Artificial Intelligence Initial Public Offering
Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills
Via Stocktwits
Topics Government
AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes
Via Benzinga
Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood
Via Stocktwits

Frequently Asked Questions

Is AbbVie publicly traded?
Yes, AbbVie is publicly traded.
What exchange does AbbVie trade on?
AbbVie trades on the New York Stock Exchange
What is the ticker symbol for AbbVie?
The ticker symbol for AbbVie is ABBV on the New York Stock Exchange
What is the current price of AbbVie?
The current price of AbbVie is 192.45
When was AbbVie last traded?
The last trade of AbbVie was at 07/11/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.